410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)
Year: 2026
Type: article
Abstract: At the first interim analysis of ADRIATIC, consolidation D significantly improved dual primary endpoints of OS (HR 0.73 [95% CI 0.57–0.93]; p=0.0104) and PFS (HR 0.76 [95% CI 0.61–0.95]; p=0.0161) vs placebo (P) in pts with LS-SCLC and no progression after cCRT. We describe patterns of subsequent tx and explore their effect on pt outcomes.
Source: ESMO Open
Institutions: Sarah Cannon, Yonsei University, Yonsei Cancer Hospital, Russian Cancer Research Center NN Blokhin, Ministry of Health of the Russian Federation, Peking University Cancer Hospital, National Cancer Center Hospital East, Chungbuk National University, Chungbuk National University Hospital, Zhengzhou University, Henan Cancer Hospital, Hospital Universitario Virgen del Rocío, Kyushu University Hospital, Akdeniz University, Istanbul University-Cerrahpaşa, Istanbul University, Ospedale San Luigi Gonzaga, University of Turin, German Center for Lung Research, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, AstraZeneca (United States), Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
Funder: AstraZeneca
OpenAlex ID: W7138198965
FWCI:
Cites:
Cited by:
Related to: